Study Information

An open-label, non-randomized, multi-center pivotal Phase 3 study to evaluate the efficacy and safety of PET imaging with [18F]PI-2620 for the detection of tau deposition when compared to post-mortem histopathology

 

Inclusion Criteria

•  Age: 50 and over
•  Targets: Prognosis <12mo.
•  AD MEDS: No amyloid or tau targeting therapies
•  Clinical Trials: No amyloid or tau targeting studies unless proof of placebo can be provided.
•  Study Partner: Required
•  Mechanism of Action: Next-generation positron emitting radiopharmaceutical for specific and sensitive in vivo detection of tau protein aggregates in the brain.

Exclusion Criteria

• Neurological Disease History: Structural brain lesions >2cm. Encephalopathy due to EtOH or end-stage liver disease
• Cancer History: N/A
• Geriatric Depression Scale: N/A
• HIV, HepB or HepC: N/A
• C-SSRS: N/A
• Alcohol or Drug Abuse: N/A

Apply to Participate

If you are interested in participating in this study, please complete the following preliminary qualification form.

We will follow-up with you after we have received your submission.